by DataCorps Support | Aug 20, 2025 | Press Releases
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA”), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present...
by DataCorps Support | Aug 14, 2025 | Press Releases
Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named “TBS-2025;” planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid Leukemia (AML) in combination with a menin inhibitor...
by DataCorps Support | Jul 1, 2025 | Press Releases
TAMPA, Fla., July 1, 2025 — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the...
by DataCorps Support | Jun 30, 2025 | Press Releases
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA’s late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the...
by DataCorps Support | Jun 24, 2025 | Press Releases
Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated approval process Key secondary endpoint of Progression Free...
by DataCorps Support | Jun 23, 2025 | Press Releases
TAMPA, Fla. and SEATTLE, June 23, 2025 — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced...
